Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H24N6 |
InChIKeyCKXSRLUXTFDZCF-UHFFFAOYSA-N |
CAS Registry2230854-93-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | IT | 12 Nov 2020 |